

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (EF-60) MARSTACIMAB

PRONUNCIATION mar stak' i mab

THERAPEUTIC CLAIM Preventing bleeding in patients with hemophilia

## CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human tissue factor pathway inhibitor) (human monoclonal PF-06741086  $\gamma$ 1-chain), disulfide with human monoclonal PF-06741086  $\lambda$ -chain, dimer
2. Immunoglobulin G1-lambda, anti-(human tissue factor pathway inhibitor (TFPI, extrinsic pathway inhibitor, EPI, lipoprotein-associated coagulation inhibitor, LACI)); human monoclonal antibody;  $\gamma$ 1 heavy chain (1-449) [human VH (*Homo sapiens* IGHV-23\*01-(IGHD)-IGHJ3\*02) [8.8.13] (1-120) -*Homo sapiens* IGHG1\*03 {CH1 R<sup>97</sup>>K(217), CH2 L<sup>4</sup>>A(237), L<sup>5</sup>>A(238), G<sup>7</sup>>A(240), CH3 K<sup>107</sup>>-(del)} (121-449)] (223-217')-disulfide with lambda light chain (1'-218') [human V-LAMBDA (*Homo sapiens* IGLV1-40\*01-IGLJ2\*01) [9.3.12] (1'-112') -*Homo sapiens* IGLC2\*01 (113'-218')] dimer (229-229':232-232')-bisdisulfide

## STRUCTURAL FORMULA

### Heavy chain

EVQLLESGGG	LVQPGGSLRL	SCAASGFTFS	SYAMSWVRQA	PGKLEWVSA	50
ISGSGGSTYY	ADSVKGRFTI	SRDNSKNTLY	LQMNSLRAED	TAVYYCAILG	100
ATSLSAFDIW	GQGTMTVTVSS	ASTKGPSVFP	LAPSSKSTSG	GTAALGCLVK	150
DYFPEPVTVS	WNSGALTSKV	HTFPAVLQSS	GLYSLSVVVT	VPSSSLGTQT	200
YICNVNHKPS	NTKVDKKEP	KSCDKTHTCP	PCPAPEAAGA	PSVFLFPPKP	250
KDTLMISRTP	EVTCTVVDVS	HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN	300
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ	350
VYTLPPSREE	MTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTTPV	400
LDSGGSFFLY	SKLTVDKSRW	QQGNVFSQSV	MHEALHNHYT	QKSLSLSPG	449

### Light chain

QSVLTQPPSV	SGAPQRVTI	SCTGSSSNIG	AGYDVHWYQQ	LPGTAPKLLI	50'
YGNSNRPSGV	PDRFSGSKSG	TSASLAITGL	QAEDADYYC	QSYDSSLGSG	100'
GVFGGGTKLT	VLGQPKAAPS	VTLFPPSSEE	LQANKATLVC	LISDFYPGAV	150'
TVAWKADSSP	VKAGVETTPP	SKQSNKYYAA	SSYLSLTPEQ	WKSHRYSYSCQ	200'
VTHEGSTVEK	TVAPTECS				218'

### Disulfide bridges

22'-90"	22"-90"	22-96	22"-96"	140'-199'	140"-199"	147-203	147"-203"
217'-223	217"-223"	229-229"	232-232"	264-324	264"-324"	370-428	370"-428"

### Modified residues



### Glycosylation sites (N)

Asn-300 Asn-300"

MOLECULAR FORMULA	C <sub>6304</sub> H <sub>9766</sub> N <sub>1678</sub> O <sub>2006</sub> S <sub>44</sub> (nonglycosylated)
MOLECULAR WEIGHT	142.6 kDa (nonglycosylated)
TRADEMARK	None as yet
SPONSOR	Pfizer Inc.
CODE DESIGNATIONS	PF-06741086
<u>CAS</u> REGISTRY NUMBER	1985638-39-8
UNII	0UB30A6707
WHO NUMBER	10789

gbk